Skip to main content
Jason Bierenbaum, MD, Oncology, McKeesport, PA

JasonBierenbaumMD

Oncology McKeesport, PA

Hematologist/Oncologist, Clinical Instructor of Medicine

Dr. Bierenbaum is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bierenbaum's full profile

Already have an account?

  • Office

    1500 5th Ave
    McKeesport, PA 15132
    Phone+1 412-664-2607
    Fax+1 412-664-2329

Education & Training

  • University of Maryland
    University of MarylandFellowship, Hematology and Medical Oncology, 2008 - 2011
  • UPMC Medical Education
    UPMC Medical EducationResidency, Internal Medicine, 2004 - 2007
  • Eastern Virginia Medical School
    Eastern Virginia Medical SchoolClass of 2004
  • Old Dominion University
    Old Dominion UniversityB.S., Biology, Summa Cum Laude, 2000

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2004 - 2024
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Travel Award ASCO, 2010
  • Travel Award National Institute on Alcohol Abuse and Alcoholism, 2006

Publications & Presentations

PubMed

Journal Articles

  • Tertiary center referral patterns for patients with myelodysplastic syndrome are indicative of age and race disparities: a single-institution experience.  
    Zandberg DP, Hendrick F, Vannorsdall E, Bierenbaum J, Tidwell ML, Ning Y, Zhao XF, Davidoff AJ, Baer MR, Leuk Lymphoma, 2/1/2013
  • Racial differences in presentation, referral and treatment patterns and survival in adult patients with acute myeloid leukemia: a single-institution experience.  
    Bierenbaum J, Davidoff AJ, Ning Y, Tidwell ML, Gojo I, Baer MR, Leuk Res, 2/1/2012
  • Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes.  
    Davidoff AJ, Weiss Smith S, Baer MR, Ke X, Bierenbaum JM, Hendrick F, McNally DL, Gore SD, Haematologica, 1/1/2012
  • Join now to see all

Abstracts/Posters

  • The broad use of erythropoietic stimulating agents (ESA) for myelodysplastic syndromes (MDS) in the U.S. is not consistent with guidelines.
    A.J. Davidoff, M.R. Baer, S.R. Weiss Smith, X. Ke, J. Bierenbaum, F. Hendrick, D. McNally, S.D. Gore, 11th Annual International Symposium on Myelodysplastic Syndromes, Edinburgh, UK., 5/19/2011
  • Race and Overall Survival in Acute Myeloid Leukemia.
    J Bierenbaum, Y Ning, M Tidwell, I Gojo, MR Baer, American Society of Clinical Oncology Annual Meeting, Chicago, IL., 1/1/2010
  • Access to Care, Race and Education Are Key Determinants of Erythropoietin Stimulating Agent (ESA) Use In Myelodysplastic Syndromes (MDS).
    A Davidoff, S Smith, MR Baer, X Ke, J Bierenbaum, F Hendrick, D McNally, S Gore, American Society of Hematology Annual Meeting, Orlando, FL., 1/1/2010
  • Join now to see all

Lectures

  • Racial Disparities in Cancer: More than a Black and White Issue. 
    Hematology and Oncology Grand Rounds, University of Maryland School of Medicine. - 3/14/2011